Pharmaceutics 2011, 3(3), 458-473; doi:10.3390/pharmaceutics3030458
Article

Fourth Generation Phosphorus-Containing Dendrimers: Prospective Drug and Gene Delivery Carrier

1 Institute of Biophysics and Cell Engineering of Natl. Acad. Sci, Minsk, Belarus 2 Department of Clinical Neuroscience, Faculty of Medicine, University of Calgary, Calgary, Canada 3 Republic Center for Hematology and Transfusiology, Minsk, Belarus 4 Department of General Biophysics, University of Lodz, Lodz, Poland 5 City Hospital of Emergency Help, Minsk, Belarus 6 Institute of Physiology of Natl. Acad. Sci, Minsk, Belarus 7 Laboratorie de Chimie de Coordination, CNRS, Toulouse, France
* Author to whom correspondence should be addressed.
Received: 30 June 2011; in revised form: 25 July 2011 / Accepted: 3 August 2011 / Published: 5 August 2011
(This article belongs to the Special Issue Gene Therapy)
PDF Full-text Download PDF Full-Text [197 KB, Updated Version, uploaded 8 August 2011 05:39 CEST]
The original version is still available [377 KB, uploaded 5 August 2011 16:02 CEST]
Abstract: Research concerning new targeting delivery systems for pharmacologically active molecules and genetic material is of great importance. The aim of the present study was to investigate the potential of fourth generation (P4) cationic phosphorus-containing dendrimers to bind fluorescent probe 8-anilino-1-naphthalenesulfonate (ANS), anti-neoplastic drug cisplatin, anti-HIV siRNA siP24 and its capability to deliver green fluorescent protein gene (pGFP) into cells. The interaction between P4 and ANS (as the model drug) was investigated. The binding constant and the number of binding centers per one molecule of P4 were determined. In addition, the dendriplex between P4 and anti-HIV siRNA siP24 was characterized using circular dichroism, fluorescence polarization and zeta-potential methods; the average hydrodynamic diameter of the dendriplex was calculated using zeta-size measurements. The efficiency of transfection of pGFP using P4 was determined in HEK293 cells and human mesenchymal stem cells, and the cytotoxicity of the P4-pGFP dendriplex was studied. Furthermore, enhancement of the toxic action of the anti-neoplastic drug cisplatin by P4 dendrimers was estimated. Based on the results, the fourth generation cationic phosphorus-containing dendrimers seem to be a good drug and gene delivery carrier candidate.
Keywords: phosphorus-containing dendrimer; drug delivery; gene delivery; dendriplex characterization; transfection; mesenchymal stem cells; tumor; cisplatin

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Shcharbin, D.; Dzmitruk, V.; Shakhbazau, A.; Goncharova, N.; Seviaryn, I.; Kosmacheva, S.; Potapnev, M.; Pedziwiatr-Werbicka, E.; Bryszewska, M.; Talabaev, M.; Chernov, A.; Kulchitsky, V.; Caminade, A.-M.; Majoral, J.-P. Fourth Generation Phosphorus-Containing Dendrimers: Prospective Drug and Gene Delivery Carrier. Pharmaceutics 2011, 3, 458-473.

AMA Style

Shcharbin D, Dzmitruk V, Shakhbazau A, Goncharova N, Seviaryn I, Kosmacheva S, Potapnev M, Pedziwiatr-Werbicka E, Bryszewska M, Talabaev M, Chernov A, Kulchitsky V, Caminade A-M, Majoral J-P. Fourth Generation Phosphorus-Containing Dendrimers: Prospective Drug and Gene Delivery Carrier. Pharmaceutics. 2011; 3(3):458-473.

Chicago/Turabian Style

Shcharbin, D.; Dzmitruk, V.; Shakhbazau, A.; Goncharova, N.; Seviaryn, I.; Kosmacheva, S.; Potapnev, M.; Pedziwiatr-Werbicka, E.; Bryszewska, M.; Talabaev, M.; Chernov, A.; Kulchitsky, V.; Caminade, A.-M.; Majoral, J.-P. 2011. "Fourth Generation Phosphorus-Containing Dendrimers: Prospective Drug and Gene Delivery Carrier." Pharmaceutics 3, no. 3: 458-473.

Pharmaceutics EISSN 1999-4923 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert